FDA Approps Amendment Targets Chief Counsel Troy
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts